<DOC>
	<DOCNO>NCT00263198</DOCNO>
	<brief_summary>The purpose study test safety PTK787/ZK222584 Letrozole give combination , see effect breast cancer metastasize .</brief_summary>
	<brief_title>PTK Letrozole Post-menopausal Women With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal woman metastatic breast cancer , locoregional disease recurrence amenable treatment surgery radiotherapy . Postmenopausal status define follow criterion : spontaneous menses least 5 year spontaneous menses within past 5 year amenorrheic least 12 month estradiol and/or FSH value postmenopausal range ( aromatase inhibitor therapy ; level take tamoxifen case estradiol parameter assess ) bilateral oophorectomy radiation castration amenorrheic least 3 month use LHRH agonist throughout duration trial ( example goserelin 3.6 mg s.c. monthly ) Age ≥ 18 year old Patients whose tumor either estrogenreceptor ( ER ) and/or progesteronereceptor ( PgR ) positive ( 10 % infiltrate cancer cell exhibit nuclear staining ) . Patients regard ER PgR positive long least one tissue assess positive . A positive biochemical test also acceptable . Patients must WHO Performance Status Grade 02 Newly diagnose patient initiate first line treatment patient know disease show resistance anti estrogen therapy ( tamoxifen toremifine ) . Patients currently receive letrozole alternative aromatase inhibitor initial therapy without evidence progressive disease eligible . Patients boneonly metastasis eligible . Laboratory value ≤ 2 week prior randomization : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L ( ≥ 1500/mm3 ) Platelets ( PLT ) ≥ 100 x 109/L ( ≥ 100,000/mm3 ) Hemoglobin ( Hgb ) ≥ 9 g/dL Serum creatinine ≤ 1.5 ULN Serum bilirubin ≤ 1.5 ULN Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) ≤ 3.0 x ULN ( ≤ 5 x ULN liver metastasis present ) Negative proteinuria base dip stick reading OR , documentation +1 result protein dip stick reading , total urinary protein 500 mg measure creatinine clearance ( CrCl ) ≥ 50 mL/min 24 hour urine collection Life expectancy ≥ 12 week Written inform consent obtain accord local guideline Patients tumor estrogen progesterone receptor negative , estrogen receptor negative progesterone receptor unknown estrogen receptor unknown progesterone receptor negative Patients history adrenalectomy hypophysectomy Patients develop progressive disease treat aromatase inhibitor . Patients follow : Absolute Neutrophil Count &lt; 1.5 x 109/L Hemoglobin &lt; 9 g/dl Platelet count &lt; 100 x 109/L AST ALT &gt; 3 time upper limit normal &gt; 5 time upper limit normal liver metastasis present Bilirubin &gt; 1.5 upper limit normal Creatinine &gt; 1.5 x upper limit normal Calcium &gt; 11.6 mg/dL History presence central nervous system ( CNS ) disease ( i.e. , primary brain tumor , malignant seizure , CNS metastases carcinomatous meningitis ) Patients history another primary malignancy ≤ 5 year treat curative intent chance long term remission judge less 50 % . Prior chemotherapy &lt; 3 week prior registration and/or randomization . Patients must recover therapyrelated toxicity Prior biologic immunotherapy ≤ 2 week prior registration and/or randomization . Patients must recover therapyrelated toxicity Patients history treatment Fulvestrant Trastuzumab &lt; 6 month prior registration . Patients must recover therapy related toxicity order enrol . Prior full field radiotherapy ≤ 4 week limited field radiotherapy ≤ 2 week prior randomization . Patients must recover therapyrelated toxicity . The site previous radiotherapy evidence progressive disease site disease Major surgery ( e.g. , laparotomy ) ≤ 4 week prior randomization . Minor surgery ≤ 2 week prior randomization . Insertion vascular access device consider major minor surgery regard . Patients must recover surgeryrelated toxicity Patients receive investigational drug ≤ 4 week prior registration and/or randomization Prior therapy antiVEGF agent Peripheral neuropathy functional impairment ≥ CTC grade 2 neuropathy , regardless causality Pleural effusion ascites cause respiratory compromise ( ≥ CTC grade 2 dyspnea ) Any follow concurrent severe and/or uncontrolled medical condition could compromise participation study : Uncontrolled high blood pressure ( systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 95 mmHg ) , history labile hypertension , history poor compliance antihypertensive regimen Unstable angina pectoris Symptomatic congestive heart failure Myocardial infarction ≤ 6 month prior registration and/or randomization Serious uncontrolled cardiac arrhythmia Uncontrolled diabetes ( fast blood sugar &gt; 300 mg/dl ) Active uncontrolled infection Interstitial pneumonia extensive symptomatic interstitial fibrosis lung Patients prolong QTc &gt; 470 msec EKG . All patient history congenital acquire long QTc syndrome . Chronic renal disease Acute chronic liver disease ( e.g. , hepatitis , cirrhosis ) Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption PTK787/ZK 222584 ( i.e. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , bowel obstruction , inability swallow tablet ) Patients confirm diagnosis human immunodeficiency virus ( HIV ) infection exclude investigator 's discretion felt : 1 ) potential drug interaction PTK787/ZK 222584 patient 's antiHIV medication could influence efficacy antiHIV medication , 2 ) may place patient risk due pharmacologic activity PTK787/ZK 222584 . Please refer appendix list example substrates human liver microsomal P450 enzymes Patients take therapeutic warfarin sodium ( Coumadin ) similar oral anticoagulant metabolize cytochrome P450 system . Heparin formulation allow . Please refer appendix list example substrates human liver microsomal P450 enzymes Patients P450 enzyme induce antiepileptic Patients unwilling unable comply protocol requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>